Coherus’ Yusimry was first approved in 2021 and is the seventh FDA-approved Humira biosimilar and Image Credit: Michael Vi / Shutterstock.

Coherus BioSciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF) in an all cash deal of $40m.

The moves come as Coherus plans to become an oncology-only focused company. To that end, the company also sold its ophthalmology portfolio to Sandoz for $170m in January. The sale included Cimerli (ranibizumab-eqrn), a biosimilar to Roche’s Lucentis, which has been approved for a variety of retinal indications including wet age-related macular degeneration, diabetic macular oedema, and diabetic retinopathy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Following the deal conclusion, HKF’s US subsidiary, Meitheal Pharmaceuticals will have exclusive commercial rights to Yusimry in the US. The companies have invested in expanding their biologics portfolio and capabilities in recent years. In September 2023, Meitheal acquired the US rights to three insulin biosimilars from China-based Tonghua Dongbao Pharmaceutical. The US approval for these biosimilars is expected in 2026.

Yusimry is a tumour necrosis factor (TNF) blocker and has been approved for nine indications – to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. Meitheal also plans to develop paediatric presentations and a high concentration (100mg/mL) formulation of Yusimry.

Humira was a blockbuster drug for AbbVie, having generated $187bn in sales from 2002, when it was first approved by the US Food and Drug Administration (FDA), to 2023. However, the drug’s revenue declined by 31.9% last year, compared to the previous year, per the AbbVie’s 2023 financials. The decline was attributed to biosimilar competition.

Despite the declining sales, GlobalData forecasts AbbVie to remain a market leader, and Yusimry to have global sales of $436m in 2025. Despite the expected cost savings, Humira biosimilars are expected to face market resistance in the US due to insurers’ contracting practices, and the reluctance to use them amongst some doctors and patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData is the parent company of Pharmaceutical Technology.

Coherus’ oncology portfolio consists of a Loqtorzi (toripalimab-tpzi), anti-programmed cell death protein 1 (PD-1) monoclonal antibody, and Udenyca (pegfilgrastim-cbqv), a biosimilar of Amgen’s Neulasta, a pegylated growth colony-stimulating factor indicated to treat febrile neutropenia. The company licenced these therapies from Shanghai Junshi Biosciences.